Treatment with Sofosbuvir and Daclatasvir (with or without Ribavirin) Improves Patient Reported Outcomes in Hepatitis C.
10.24171/j.phrp.2018.9.2.03
- Author:
Lucas Pereira Jorge DE MEDEIROS
1
;
Mario Barreto Correa LIMA
;
Marcia Maria Amêndola PIRES
;
Alessandra Mendonça Almeida MACIEL
;
Renata Barboza Vianna MEDEIROS
;
Mariana Dermínio DONADEL
;
Isabela Martins Becattini PEREIRA
;
Fábio Marchon LEÃO
;
Luiz Eduardo Amorim Correa Lima PIRES
;
Helio RZETELNA
;
Carlos Eduardo BRANDÃO-MELLO
Author Information
1. Federal University of Rio de Janeiro State– UNIRIO, Brazil. lucasmedeiros.medicina@gmail.com
- Publication Type:Original Article
- Keywords:
antiviral agents;
hepatitis C;
patient reported outcome measures;
quality of life
- MeSH:
Antiviral Agents;
Chronic Disease;
Efficiency;
Hepacivirus;
Hepatitis C*;
Hepatitis C, Chronic;
Hepatitis*;
Humans;
Liver Diseases;
Mental Health;
Quality of Life;
Ribavirin;
Simeprevir;
Sofosbuvir*
- From:
Osong Public Health and Research Perspectives
2018;9(2):50-58
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVES: To evaluate the impact of 3 treatment regimens upon health-related quality of life and work productivity using patient-reported outcomes (PROs) in chronic hepatitis C infected patients: sofosbuvir (SOF) + daclatasvir (DCV); SOF + DCV + ribavirin (RBV); SOF + simeprevir (SMV). METHODS: 4 questionnaires were used to evaluate PROs before, during and after treatment: Short Form-36 (SF-36), Chronic Liver Disease Questionnaire (CLDQ) - hepatitis C virus (HCV), Work Productivity and Activity Index, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F). RESULTS: Of the global sample of 55 patients included in this study; SOF + DCV (n = 10); SOF + DCV + RBV (n = 29); SOF + SMV (n = 16) all had a statistically significant improvement in SF-36, CLDQ and FACIT-F scores during and post-treatment. No statistically significant differences in the PRO questionnaire values were observed between the distinct treatment regimens. The SOF and SMV patient groups presented higher mean PRO variations during and post-treatment, compared to the other groups: SF-36 functional capacity (16.1); SF-36 mental health (21.4); CLDQ activity (1.8); CLDQ emotional function (1.2); FACIT-F physical well-being (8.0); Total FACIT-F (21.6). CONCLUSION: Treatment with SOF + DCV, with or without RBV, results in an improved PRO similar to treatment with SOF + SMV in chronic hepatitis C patients.
